Zoetis — Key Risks
Top Products Generate 42% of Revenue, Creating Dangerous Concentration Risk
Zoetis's five best-selling products — Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, and its ceftiofur line — together accounted for approximately 42% of total revenue in 2025. If any of these products faces safety concerns, a manufacturing problem, regulatory action, or a strong competitor, the financial hit would be immediate and severe.
Generic Competition Has Already Gutted Some Products, and More Is Coming
When patents expire, generic manufacturers move in fast and cheap. Zoetis has already felt this pain: U.S. sales of its Rimadyl chewable product fell 39% and Draxxin fell 66% after generics entered the market. Generic rivals are increasingly launching before patents officially expire, and this threat will keep growing as more products lose protection.
$9.2 Billion in Debt Leaves Little Room for Error
As of year-end 2025, Zoetis carried approximately $9.2 billion in unsecured debt. That level of leverage (borrowed money) increases vulnerability to downturns, limits flexibility to invest or make acquisitions, and means a meaningful portion of cash flow must go toward debt payments rather than growth.
Antibacterial Products Face Regulatory and Consumer Pressure
Zoetis generated approximately $713 million in revenue from antibacterials (antibiotics used in livestock) in 2025. Growing concerns about antibiotic resistance in humans — and the policies responding to those concerns — have already led to restrictions in the U.S., EU, U.K., China, and other markets. Consumer preference for antibiotic-free meat is also rising, which reduces demand from livestock producers.
Nearly Half of Revenue Is Earned in Foreign Currencies
Approximately 42% of 2025 revenue came in currencies other than the U.S. dollar, including the euro, Brazilian real, and Chinese renminbi. When the dollar strengthens, those earnings are worth less when converted. On top of that, some countries where Zoetis operates restrict companies from moving cash out, including China.
Animal Disease Outbreaks Can Rapidly Shrink the Customer Base
An outbreak of a contagious disease — like avian influenza or African Swine Fever — can lead to mass animal deaths or culling, shrinking the livestock populations that Zoetis sells to. This is not theoretical: these diseases have already disrupted the animal health business in recent years and could do so again.
A Multi-Year ERP System Overhaul Adds Near-Term Operational Risk
Zoetis is in the middle of migrating to a fully cloud-based enterprise resource planning (ERP) system — the software backbone that runs finance, manufacturing, and supply chain operations. These transitions are notoriously complex and can cause billing errors, production delays, and data problems. A significant disruption during the transition could affect operations and financial reporting.